Farmas USA

                                      Futures inch up ahead of Fed statement

With the Fed set to hike its benchmark interest rate for a second time this year, the focus today will turn to Chairman Jerome Powell's press conference.

New projections could show the central bank tilting toward four increases in 2018, rather than the three hinted to in March.

Investors may also render a "hawkish" view if the Fed sounds more optimistic on the economy, raises its interest rate forecast, or announces that Powell will hold press conferences after every meeting.

U.S. stock index futures are up slightly ahead of the statement, while oil, gold and the 10-year Treasury yield hold steady

https://seekingalpha.com/news/3363521-futures-inch-ahead-fed-statement?app=1#email_link

PGNX

¿Alguien la sigue? Se acreca la fecha de la decisión de la FDA sobre Azedra (antes del 30/7), y estoy por salirme para ver los toros desde la barrera.

No se si se sigue a Pluristem PSTI aqui o en el hilo de chicharros USA. 

Por si acaso cuelgo la noticia en ambos sitios.

The Israeli biotech Pluristem has Phase II data indicating that its cell therapy made of placenta cells can help patients suffering from peripheral artery disease recover their mobility. 

https://labiotech.eu/pluristem-cell-therapy-peripheral-artery-disease/

OMER

Is It Time To Close Out The Omeros Corporation Trade?

https://seekingalpha.com/article/4181282-time-close-omeros-corporation-trade

La conclusión del autor es que NO...

I began recommending a long in OMER back in March, 2018, when the Consolidated Appropriations Act was passed by the House of Representatives (the bill included a provision to extend pass-through reimbursement for select drugs which lost pass-through at year end 2017, which included Omidria). Since that time OMER has generally performed quite well, particularly with the update suggesting the company might soon file a BLA for OMS721 in HSCT-TMA. I expect OMER to continue to perform well and additional phase 2 data in IgAN is the near-term catalyst to drive that performance. I also think better than expected increases in revenues from Omidria, due to addition to the VA Formulary, could cause the stock to run at the next earnings. Finally, I think a settlement with Sandoz in the Omidria patent infringement lawsuit could also cause the stock to run. For these reasons I don't think it is time to close out a long in OMER despite the gains in recent months. There are risks however, by failing to list its phase 3 studies for IgAN in clinical trials databases and failing to update the aHUS trial entry, OMER has again opened itself up to short reports from short sellers. Unimpressive phase 2 IgAN data mid-year could also cause the stock to sell off.

Mugi , y ademas de la FED y la votacion de ayer ,tenemos esta otra  G News ,y ..mas combustible para la NASA hoy ..je,je,je 

-----

SYNERGY PHARMACEUTICALS ANNOUNCES AMENDMENT TO CRG DEBT AGREEMENT

 DOWNLOAD AS PDF

JUNE 13, 2018

NEW YORK--(BUSINESS WIRE)-- Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced that it has received a waiver to extend the draw down date of the second borrowing under its Term Loan Agreement with CRG LP from June 30, 2018 to August 29, 2018.

“This waiver provides us with additional time and flexibility while we continue to assess various strategic options that align with our commitment to maximize shareholder value,” said Gary Gemignani, EVP and Chief Financial Officer of Synergy Pharmaceuticals Inc. “We appreciate CRG’s continued support and willingness to work with us during this ongoing strategic review. We look forward to providing an update on or before we report our second quarter 2018 results on August 9th.”

Synergy has the ability to access up to $100 million in 2018 in three tranches under the amended Term Loan Agreement. The amended Term Loan Agreement provides for future potential borrowings of $25 million, $25 million and $50 million on or before August 29, 2018, September 30, 2018 and December 31, 2018, respectively, subject to the satisfaction of certain borrowing conditions.

https://ir.synergypharma.com/press-releases/detail/1871

SGYP

pues será bueno o malo en función de lo que signifique la frase “This waiver provides us with additional time and flexibility while we continue to assess various strategic options that align with our commitment to maximize shareholder value”.

Si esas opciones son partners o estrategias para alcanzar más ventas es algo bueno, pero esas opciones también pueden ser más dilución o más deuda (ya que a 31/12/2018 se acaba el préstamo y van a llegar algo justos de cash)

PGNX 

La sigo, pero  despues de ese RSI en sobre compra que coincide con la R 3 de PPivote en G Diario ,,debe tener una correccion, que para mi seria interesante para entrar, eso de cara a ese J30,, por  lo que me parece le falta recorrido aun,

Gracias Mugi 

SGYP 

pero no se le han bloqueado eas diluciones con la votacion de ayer.?

Si aumentan las ventas de Trulance podria eso influir al aumentar el cash ,? y con ello retrasar cualquier endeudamiento adicional pues mira que de deuda van cargaditos ya, eh !

---

Aqui este da otra opinion 

Synergy Pharmaceuticals: Better Days Likely Ahead, But Better Opportunities Elsewhere

https://seekingalpha.com/article/4181296-synergy-pharmaceuticals-better-days-likely-ahead-better-opportunities-elsewhere